S&P 500   4,613.12 (+0.19%)
DOW   36,355.63 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.43 (+0.68%)
BABA   71.26 (-1.22%)
AMD   133.84 (+3.82%)
T   16.61 (-1.83%)
F   11.07 (+0.54%)
MU   77.77 (+3.75%)
CGC   0.78 (-2.15%)
GE   120.21 (-0.32%)
DIS   92.53 (-0.31%)
AMC   6.78 (-2.16%)
PFE   28.45 (-1.15%)
PYPL   59.49 (+0.93%)
XOM   99.14 (-0.41%)
S&P 500   4,613.12 (+0.19%)
DOW   36,355.63 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.43 (+0.68%)
BABA   71.26 (-1.22%)
AMD   133.84 (+3.82%)
T   16.61 (-1.83%)
F   11.07 (+0.54%)
MU   77.77 (+3.75%)
CGC   0.78 (-2.15%)
GE   120.21 (-0.32%)
DIS   92.53 (-0.31%)
AMC   6.78 (-2.16%)
PFE   28.45 (-1.15%)
PYPL   59.49 (+0.93%)
XOM   99.14 (-0.41%)
S&P 500   4,613.12 (+0.19%)
DOW   36,355.63 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.43 (+0.68%)
BABA   71.26 (-1.22%)
AMD   133.84 (+3.82%)
T   16.61 (-1.83%)
F   11.07 (+0.54%)
MU   77.77 (+3.75%)
CGC   0.78 (-2.15%)
GE   120.21 (-0.32%)
DIS   92.53 (-0.31%)
AMC   6.78 (-2.16%)
PFE   28.45 (-1.15%)
PYPL   59.49 (+0.93%)
XOM   99.14 (-0.41%)
S&P 500   4,613.12 (+0.19%)
DOW   36,355.63 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.43 (+0.68%)
BABA   71.26 (-1.22%)
AMD   133.84 (+3.82%)
T   16.61 (-1.83%)
F   11.07 (+0.54%)
MU   77.77 (+3.75%)
CGC   0.78 (-2.15%)
GE   120.21 (-0.32%)
DIS   92.53 (-0.31%)
AMC   6.78 (-2.16%)
PFE   28.45 (-1.15%)
PYPL   59.49 (+0.93%)
XOM   99.14 (-0.41%)

UroGen Pharma (URGN) Stock Price, News & Analysis

$14.10
-0.17 (-1.19%)
(As of 10:39 AM ET)
Compare
Today's Range
$13.93
$14.35
50-Day Range
$10.87
$14.44
52-Week Range
$7.15
$24.13
Volume
34,610 shs
Average Volume
310,370 shs
Market Capitalization
$330.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00

UroGen Pharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
162.4% Upside
$37.00 Price Target
Short Interest
Bearish
12.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.54) to ($2.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

657th out of 942 stocks

Pharmaceutical Preparations Industry

304th out of 424 stocks


URGN stock logo

About UroGen Pharma Stock (NASDAQ:URGN)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN Stock Price History

URGN Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
UroGen Pharma Ltd. Q3 Loss decreases, beats estimates
UroGen Pharma Reports Third Quarter 2023 Financial Results
Preview: UroGen Pharma's Earnings
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
The Latest Analyst Ratings for UroGen Pharma
UroGen Pharma (NASDAQ: URGN)
Goldman Sachs Remains a Hold on Urogen Pharma (URGN)
UroGen Pharma Ltd. Q2 Loss decreases, beats estimates
See More Headlines
Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:URGN
Fax
N/A
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.00
High Stock Price Target
$54.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+162.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-109,780,000.00
Net Margins
-135.20%
Pretax Margin
-135.03%

Debt

Sales & Book Value

Annual Sales
$64.36 million
Book Value
($3.93) per share

Miscellaneous

Free Float
20,844,000
Market Cap
$330.65 million
Optionable
Optionable
Beta
1.00
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives















URGN Stock Analysis - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" URGN shares.
View URGN analyst ratings
or view top-rated stocks.

What is UroGen Pharma's stock price target for 2024?

3 Wall Street research analysts have issued 1 year target prices for UroGen Pharma's stock. Their URGN share price targets range from $10.00 to $54.00. On average, they anticipate the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 162.4% from the stock's current price.
View analysts price targets for URGN
or view top-rated stocks among Wall Street analysts.

How have URGN shares performed in 2023?

UroGen Pharma's stock was trading at $8.87 at the beginning of the year. Since then, URGN shares have increased by 59.0% and is now trading at $14.10.
View the best growth stocks for 2023 here
.

Are investors shorting UroGen Pharma?

UroGen Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,830,000 shares, an increase of 23.6% from the October 31st total of 2,290,000 shares. Based on an average daily volume of 248,800 shares, the days-to-cover ratio is currently 11.4 days.
View UroGen Pharma's Short Interest
.

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our URGN earnings forecast
.

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) announced its earnings results on Tuesday, November, 14th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.21. The firm earned $20.85 million during the quarter, compared to analysts' expectations of $19.80 million.

What ETF holds UroGen Pharma's stock ?

ARK Israel Innovative Technology ETF holds 218,434 shares of URGN stock, representing 1.96% of its portfolio.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.33%), Harel Insurance Investments & Financial Services Ltd. (3.71%), Migdal Insurance & Financial Holdings Ltd. (2.76%), Silverarc Capital Management LLC (2.17%), Laurion Capital Management LP (1.62%) and Clal Insurance Enterprises Holdings Ltd (0.95%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg and Molly Henderson.
View institutional ownership trends
.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:URGN) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -